<DOC>
	<DOCNO>NCT01301638</DOCNO>
	<brief_summary>Before Daptomycin ( Cubicin Â® ) approve U.S. FDA 2003 , There large-scale clinical trial conduct include 1,000 subject Daptomycin get complicate skin soft tissue infection ( CSSSI ) indication . After 2004 , Daptomycin get new indication bacteremia endocarditis due success outcomes clinical trial include infected blood flow endocardial infected patient . All subject Daptomycin clinical trial European American race . It necessary collect safety efficacy data Daptomycin Taiwan race . I intent evaluate safety efficacy Daptomycin use patient serious gram-positive infection retrospectively . And outcome could reference Daptomycin future use .</brief_summary>
	<brief_title>Retrospective Evaluation Safety Efficacy Daptomycin Used Patients With Serious Gram-positive Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Endocarditis</mesh_term>
	<criteria>Hospitalized patient prescribe daptomycin 1st January 2009 31st December 2010 gram positive infection deem necessary his/her treat physician . And patient receive Daptomycin therapy least 3 day . Patients receive Daptomycin therapy 3 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>